You are using an unsupported browser. Please upgrade your browser to a newer version to get the best experience on DrugBank.
Identification
NameMethimazole
Accession NumberDB00763  (APRD00002)
TypeSmall Molecule
GroupsApproved
Description

A thioureylene antithyroid agent that inhibits the formation of thyroid hormones by interfering with the incorporation of iodine into tyrosyl residues of thyroglobulin. This is done by interfering with the oxidation of iodide ion and iodotyrosyl groups through inhibition of the peroxidase enzyme. [PubChem]

Structure
Thumb
Synonyms
1-METHYL-1,3-dihydro-2H-imidazole-2-thione
1-Methylimidazole-2(3H)-thione
Danantizol
Favistan
Mercazolyl
Methimazole
Strumazol
Tapazole
Thacapzol
Thiamazol
Thiamazole
Thiamazolum
Tiamazol
USAF el-30
External Identifiers
  • NSC 38608
  • UNII-554Z48XN5E
Approved Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Dom-methimazoletablet5 mgoralDominion PharmacalNot applicableNot applicableCanada
PHL-methimazoletablet5 mgoralPharmel IncNot applicableNot applicableCanada
PMS-methimazoletablet5 mgoralPharmascience Inc2004-11-052005-05-04Canada
Tapazoletablet10 mgoralPaladin Labs Inc2008-01-07Not applicableCanada
Tapazoletablet20 mgoralPaladin Labs IncNot applicableNot applicableCanada
Tapazole 5mg Tablettablet5 mgoralPaladin Labs Inc1951-12-31Not applicableCanada
Approved Generic Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Apo-methimazoletablet5 mgoralApotex Inc2005-03-18Not applicableCanada
Methimazoletablet10 mg/1oralPar Pharmaceutical2012-02-28Not applicableUs
Methimazoletablet5 mg/1oralBoca Pharmacal, LLC2012-03-07Not applicableUs
Methimazoletablet5 mg/1oralRising Pharmaceuticals, Inc.2015-09-28Not applicableUs
Methimazoletablet5 mg/1oralEon Labs, Inc.2001-03-27Not applicableUs
Methimazoletablet10 mg/1oralREMEDYREPACK INC.2013-03-18Not applicableUs
Methimazoletablet5 mg/1oralPreferred Pharmaceuticals Inc.2015-10-06Not applicableUs
Methimazoletablet10 mg/1oralState of Florida DOH Central Pharmacy2014-01-01Not applicableUs
Methimazoletablet5 mg/1oralPar Pharmaceutical2012-02-28Not applicableUs
Methimazoletablet10 mg/1oralbryant ranch prepack2010-07-07Not applicableUs
Methimazoletablet10 mg/1oralHeritage Pharmaceuticals Inc.2012-01-16Not applicableUs
Methimazoletablet10 mg/1oralPreferred Pharmaceuticals, Inc.2014-02-27Not applicableUs
Methimazoletablet10 mg/1oralState of Florida DOH Central Pharmacy2014-01-01Not applicableUs
Methimazoletablet10 mg/1oralREMEDYREPACK INC.2011-11-01Not applicableUs
Methimazoletablet5 mg/1oralHeritage Pharmaceuticals Inc.2012-01-16Not applicableUs
Methimazoletablet10 mg/1oralAmerican Health Packaging2013-06-14Not applicableUs
Methimazoletablet10 mg/1oralState of Florida DOH Central Pharmacy2013-01-01Not applicableUs
Methimazoletablet10 mg/1oralExact Rx, Inc.2012-01-12Not applicableUs
Methimazoletablet10 mg/1oralNcs Health Care Of Ky, Inc Dba Vangard Labs2001-03-27Not applicableUs
Methimazoletablet5 mg/1oralAmerican Health Packaging2013-06-14Not applicableUs
Methimazoletablet5 mg/1oralREMEDYREPACK INC.2013-11-22Not applicableUs
Methimazoletablet10 mg/1oralGolden State Medical Supply Inc.2013-01-08Not applicableUs
Methimazoletablet5 mg/1oralExact Rx, Inc.2012-01-12Not applicableUs
Methimazoletablet10 mg/1oralDispensing Solutions, Inc.2012-01-16Not applicableUs
Methimazoletablet10 mg/1oralREMEDYREPACK INC.2013-07-03Not applicableUs
Methimazoletablet5 mg/1oralNcs Health Care Of Ky, Inc Dba Vangard Labs2001-03-27Not applicableUs
Methimazoletablet5 mg/1oralGolden State Medical Supply Inc.2013-01-08Not applicableUs
Methimazoletablet10 mg/1oralRebel Distributors Corp.2010-07-07Not applicableUs
Methimazoletablet10 mg/1oralUnit Dose Services2001-03-27Not applicableUs
Methimazoletablet10 mg/1oralBoca Pharmacal, LLC2012-03-07Not applicableUs
Methimazoletablet10 mg/1oralRising Pharmaceuticals, Inc.2015-09-28Not applicableUs
Methimazoletablet10 mg/1oralEon Labs, Inc.2001-03-27Not applicableUs
Methimazoletablet5 mg/1oralPhysicians Total Care, Inc.2009-10-13Not applicableUs
Methimazoletablet5 mg/1oralRebel Distributors Corp.2010-07-07Not applicableUs
Tapazoletablet5 mg/1oralREMEDYREPACK INC.2013-02-18Not applicableUs
Tapazoletablet10 mg/1oralPfizer Laboratories Div Pfizer Inc2000-03-31Not applicableUs
Tapazoletablet5 mg/1oralPfizer Laboratories Div Pfizer Inc2000-03-31Not applicableUs
Tapazoletablet10 mg/1oralREMEDYREPACK INC.2013-03-13Not applicableUs
Approved Over the Counter ProductsNot Available
Unapproved/Other Products Not Available
International Brands
NameCompany
DanantizolGador S.A.
FavistanTemmler
MetizolICN
StrumazolOrganon
StrumazoleNot Available
ThacapzolRecip
ThycapzolSandoz
ThyrozolMerck
TirozolMerck
Brand mixturesNot Available
SaltsNot Available
Categories
UNII554Z48XN5E
CAS number60-56-0
WeightAverage: 114.169
Monoisotopic: 114.025168892
Chemical FormulaC4H6N2S
InChI KeyInChIKey=PMRYVIKBURPHAH-UHFFFAOYSA-N
InChI
InChI=1S/C4H6N2S/c1-6-3-2-5-4(6)7/h2-3H,1H3,(H,5,7)
IUPAC Name
1-methyl-2,3-dihydro-1H-imidazole-2-thione
SMILES
CN1C=CNC1=S
Taxonomy
DescriptionThis compound belongs to the class of organic compounds known as n-substituted imidazoles. These are heterocyclic compounds containing an imidazole ring substituted at position 1.
KingdomOrganic compounds
Super ClassOrganoheterocyclic compounds
ClassAzoles
Sub ClassImidazoles
Direct ParentN-substituted imidazoles
Alternative Parents
Substituents
  • N-substituted imidazole
  • Heteroaromatic compound
  • Azacycle
  • Arylthiol
  • Hydrocarbon derivative
  • Organosulfur compound
  • Organonitrogen compound
  • Aromatic heteromonocyclic compound
Molecular FrameworkAromatic heteromonocyclic compounds
External Descriptors
Pharmacology
IndicationFor the treatment of hyperthyroidism, goiter, Graves disease and psoriasis.
PharmacodynamicsUsed in the treatment of hyperthyroidism or an overactive thyroid gland, methimazole inhibits the synthesis of thyroid hormones and thus is effective in the treatment of hyperthyroidism. It may also be used to ameliorate hyperthyroidism in preparation for subtotal thyroidectomy or radioactive iodine therapy.
Mechanism of actionMethimazole binds to thyroid peroxidase and thereby inhibits the conversion of iodide to iodine. Thyroid peroxidase normally converts iodide to iodine (via hydrogen peroxide as a cofactor) and also catalyzes the incorporation of the resulting iodide molecule onto both the 3 and/or 5 positions of the phenol rings of tyrosines found in thyroglobulin. Thyroglobulin is degraded to produce thyroxine (T4) and tri-iodothyronine (T3), which are the main hormones produced by the thyroid gland. So methimazole effectively inhibits the production of new thyroid hormones.
Related Articles
AbsorptionRapid with an oral bioavailability of 93%.
Volume of distributionNot Available
Protein bindingNone or minimal
Metabolism

Primarily hepatic. Metabolized rapidly, requiring frequent administration.

Route of eliminationMethimazole is excreted in the urine.
Half life5-6 hours
ClearanceNot Available
ToxicityOral LD50 in rats is 2250 mg/kg. Symptoms of overdose include nausea, vomiting, epigastric distress, headache, fever, joint pain, pruritus, and edema. Aplastic anemia (pancy-topenia) or agranulocytosis may be manifested in hours to days. Less frequent events are hepatitis, nephrotic syndrome, exfoliative dermatitis, neuropathies, and CNS stimulation or depression.
Affected organisms
  • Humans and other mammals
PathwaysNot Available
SNP Mediated EffectsNot Available
SNP Mediated Adverse Drug ReactionsNot Available
ADMET
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.9156
Blood Brain Barrier+0.9731
Caco-2 permeable+0.6156
P-glycoprotein substrateNon-substrate0.8213
P-glycoprotein inhibitor INon-inhibitor0.7552
P-glycoprotein inhibitor IINon-inhibitor0.944
Renal organic cation transporterNon-inhibitor0.7662
CYP450 2C9 substrateNon-substrate0.7919
CYP450 2D6 substrateNon-substrate0.8985
CYP450 3A4 substrateNon-substrate0.7849
CYP450 1A2 substrateNon-inhibitor0.9045
CYP450 2C9 inhibitorNon-inhibitor0.9071
CYP450 2D6 inhibitorNon-inhibitor0.9232
CYP450 2C19 inhibitorNon-inhibitor0.9025
CYP450 3A4 inhibitorNon-inhibitor0.8309
CYP450 inhibitory promiscuityHigh CYP Inhibitory Promiscuity0.7105
Ames testNon AMES toxic0.8582
CarcinogenicityNon-carcinogens0.9348
BiodegradationNot ready biodegradable0.9815
Rat acute toxicity1.8215 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.9401
hERG inhibition (predictor II)Non-inhibitor0.8416
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397 )
Pharmacoeconomics
Manufacturers
  • Actavis totowa llc
  • Caraco pharmaceutical laboratories ltd
  • Cedar pharmaceuticals llc
  • Mylan pharmaceuticals inc
  • Sandoz inc
  • King pharmaceuticals inc
  • King pharmaceuticals research and development inc sub king pharmaceuticals inc
Packagers
Dosage forms
FormRouteStrength
Tabletoral5 mg
Tabletoral10 mg/1
Tabletoral5 mg/1
Tabletoral10 mg
Tabletoral20 mg
Prices
Unit descriptionCostUnit
Methimazole powder9.49USD g
Methimazole 20 mg tablet1.9USD tablet
Tapazole 10 mg tablet1.45USD tablet
Northyx 20 mg tablet0.94USD tablet
Northyx 15 mg tablet0.82USD tablet
Methimazole 10 mg tablet0.78USD tablet
Tapazole 5 mg tablet0.66USD tablet
Northyx 10 mg tablet0.47USD tablet
Methimazole 5 mg tablet0.45USD tablet
Northyx 5 mg tablet0.29USD tablet
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
PatentsNot Available
Properties
StateSolid
Experimental Properties
PropertyValueSource
melting point146 °CPhysProp
boiling point280 °CPhysProp
water solubility275 g/LNot Available
logP-0.34HANSCH,C ET AL. (1995)
Predicted Properties
PropertyValueSource
Water Solubility11.3 mg/mLALOGPS
logP-0.38ALOGPS
logP0.75ChemAxon
logS-1ALOGPS
pKa (Strongest Acidic)10.41ChemAxon
pKa (Strongest Basic)-3ChemAxon
Physiological Charge0ChemAxon
Hydrogen Acceptor Count0ChemAxon
Hydrogen Donor Count1ChemAxon
Polar Surface Area15.27 Å2ChemAxon
Rotatable Bond Count0ChemAxon
Refractivity33.23 m3·mol-1ChemAxon
Polarizability11.64 Å3ChemAxon
Number of Rings1ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleYesChemAxon
Spectra
Mass Spec (NIST)Download (8.12 KB)
Spectra
Spectrum TypeDescriptionSplash Key
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, Positivesplash10-014i-0900000000-810e7a010dd805f3251dView in MoNA
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, Positivesplash10-014i-5900000000-e88140069cbfa61f9c51View in MoNA
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, Positivesplash10-0006-9000000000-3969b3a3102e9214d562View in MoNA
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, Negativesplash10-03di-0900000000-3e543dd0166f52789fcdView in MoNA
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, Negativesplash10-0900-9300000000-90c58541a936c6fdd275View in MoNA
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, Negativesplash10-0a4i-9000000000-9a1c61f319838c2ebce9View in MoNA
References
Synthesis ReferenceNot Available
General ReferencesNot Available
External Links
ATC CodesH03BB02H03BB52
AHFS Codes
  • 68:36.08
PDB EntriesNot Available
FDA labelNot Available
MSDSDownload (75.8 KB)
Interactions
Drug Interactions
Drug
AcenocoumarolMethimazole may decrease the anticoagulant activities of Acenocoumarol.
AminophyllineThe serum concentration of Aminophylline can be increased when it is combined with Methimazole.
AripiprazoleThe serum concentration of Aripiprazole can be increased when it is combined with Methimazole.
ClozapineThe risk or severity of adverse effects can be increased when Methimazole is combined with Clozapine.
DicoumarolMethimazole may decrease the anticoagulant activities of Dicoumarol.
DigoxinThe serum concentration of Digoxin can be increased when it is combined with Methimazole.
MetamizoleThe risk or severity of adverse effects can be increased when Metamizole is combined with Methimazole.
PrednisoloneThe serum concentration of Prednisolone can be decreased when it is combined with Methimazole.
Sodium Iodide I-131The therapeutic efficacy of Sodium Iodide I-131 can be decreased when used in combination with Methimazole.
TheophyllineThe serum concentration of Theophylline can be increased when it is combined with Methimazole.
TizanidineThe serum concentration of Tizanidine can be increased when it is combined with Methimazole.
WarfarinMethimazole may decrease the anticoagulant activities of Warfarin.
Food Interactions
  • Always take at the same moment in regard to meals, food may affect absorption unpredictably.

Targets

Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
inhibitor
General Function:
Peroxidase activity
Specific Function:
Iodination and coupling of the hormonogenic tyrosines in thyroglobulin to yield the thyroid hormones T(3) and T(4).
Gene Name:
TPO
Uniprot ID:
P07202
Molecular Weight:
102961.63 Da
References
  1. Sugawara M, Sugawara Y, Wen K: Methimazole and propylthiouracil increase cellular thyroid peroxidase activity and thyroid peroxidase mRNA in cultured porcine thyroid follicles. Thyroid. 1999 May;9(5):513-8. [PubMed:10365684 ]
  2. Manzon RG, Holmes JA, Youson JH: Variable effects of goitrogens in inducing precocious metamorphosis in sea lampreys (Petromyzon marinus). J Exp Zool. 2001 Apr 15;289(5):290-303. [PubMed:11241400 ]
  3. Ferreira AC, de Carvalho Cardoso L, Rosenthal D, de Carvalho DP: Thyroid Ca2+/NADPH-dependent H2O2 generation is partially inhibited by propylthiouracil and methimazole. Eur J Biochem. 2003 Jun;270(11):2363-8. [PubMed:12755690 ]
  4. Magnusson RP, Yu B, Brennan V: Effect of serum thyrotropin levels on the concentration of messenger RNA for thyroid peroxidase in the rat. Acta Endocrinol (Copenh). 1992 May;126(5):460-6. [PubMed:1320313 ]
  5. Chiovato L, Pinchera A: The microsomal/peroxidase antigen: modulation of its expression in thyroid cells. Autoimmunity. 1991;10(4):319-31. [PubMed:1663395 ]
  6. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352 ]

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, reduced flavin or flavoprotein as one donor, and incorporation of one atom of oxygen
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics. Most active in catalyzing 2-hydroxylation. Caffeine is metabolized primarily by cytochrome CYP1A2 in the liver through an initial N...
Gene Name:
CYP1A2
Uniprot ID:
P05177
Molecular Weight:
58293.76 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Steroid hydroxylase activity
Specific Function:
Exhibits a high coumarin 7-hydroxylase activity. Can act in the hydroxylation of the anti-cancer drugs cyclophosphamide and ifosphamide. Competent in the metabolic activation of aflatoxin B1. Constitutes the major nicotine C-oxidase. Acts as a 1,4-cineole 2-exo-monooxygenase. Possesses low phenacetin O-deethylation activity.
Gene Name:
CYP2A6
Uniprot ID:
P11509
Molecular Weight:
56501.005 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Steroid hydroxylase activity
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics. Acts as a 1,4-cineole 2-exo-monooxygenase.
Gene Name:
CYP2B6
Uniprot ID:
P20813
Molecular Weight:
56277.81 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Steroid hydroxylase activity
Specific Function:
Responsible for the metabolism of a number of therapeutic agents such as the anticonvulsant drug S-mephenytoin, omeprazole, proguanil, certain barbiturates, diazepam, propranolol, citalopram and imipramine.
Gene Name:
CYP2C19
Uniprot ID:
P33261
Molecular Weight:
55930.545 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Steroid hydroxylase activity
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics. This enzyme contributes to the wide pharmacokinetics variability of the metabolism of drugs such as S-warfarin, diclofenac, phenyto...
Gene Name:
CYP2C9
Uniprot ID:
P11712
Molecular Weight:
55627.365 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Steroid hydroxylase activity
Specific Function:
Responsible for the metabolism of many drugs and environmental chemicals that it oxidizes. It is involved in the metabolism of drugs such as antiarrhythmics, adrenoceptor antagonists, and tricyclic antidepressants.
Gene Name:
CYP2D6
Uniprot ID:
P10635
Molecular Weight:
55768.94 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Steroid hydroxylase activity
Specific Function:
Metabolizes several precarcinogens, drugs, and solvents to reactive metabolites. Inactivates a number of drugs and xenobiotics and also bioactivates many xenobiotic substrates to their hepatotoxic or carcinogenic forms.
Gene Name:
CYP2E1
Uniprot ID:
P05181
Molecular Weight:
56848.42 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Vitamin d3 25-hydroxylase activity
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It performs a variety of oxidation reactions (e.g. caffeine 8-oxidation, omeprazole sulphoxidation, midazolam 1'-hydroxylation and midazolam 4-hydroxylation) of structurally unrelated compounds, including steroids, fatty acids, and xenobiot...
Gene Name:
CYP3A4
Uniprot ID:
P08684
Molecular Weight:
57342.67 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
Comments
comments powered by Disqus
Drug created on June 13, 2005 07:24 / Updated on August 17, 2016 12:23